ScreenerHero

VBIOValion Bio, Inc.

Partial data
NAS · US · Healthcare · Biotechnology · valionbio.com
2.490USD+390.16%Mkt Cap: 2.21M $P/E: —

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$130.53BUSDP/E 30.0
REGN
Regeneron Pharmaceuticals, Inc.
$82.77BUSDP/E 19.9
MRNA
Moderna, Inc.
$72.88BUSD
ARGX
argenx SE
$57.82BUSDP/E 37.5
ARGX
argenx SE
$59.94BUSDP/E 36.7
UCB
UCB SA
$44.25BUSDP/E 18.9
ONC
BeOne Medicines AG
$41.64BUSDP/E 65.8
RVMD
Revolution Medicines, Inc.
$41.34BUSD
RPRX
Royalty Pharma plc
$33.81BUSDP/E 31.5
ALNY
Alnylam Pharmaceuticals, Inc.
$33.67BUSDP/E 43.8
ROIV
Roivant Sciences Ltd.
$27.61BUSD
INSM
Insmed Incorporated
$26.38BUSD
INCY
Incyte Corporation
$25.73BUSDP/E 16.2
BNTX
BioNTech SE
$25.34BUSD
GMAB
Genmab A/S
$21.66BUSDP/E 28.0
GMAB
Genmab A/S
$20.41BUSDP/E 27.6
ASND
Ascendis Pharma A/S
$15.63BUSDP/E 18.5
JAZZ
Jazz Pharmaceuticals plc
$15.62BUSDP/E 16.5
EXEL
Exelixis, Inc.
$14.41BUSDP/E 18.3
SMMT
Summit Therapeutics Inc.
$13.66BUSD

Key Statistics

Company
Market Cap2.21M $
Enterprise Value11.38M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.88M $
Revenue/Share—
Last Price2.490 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees52
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.94
EV/Revenue—
P/S—
P/B0.13
EPS (TTM)-6.66
EPS (Forward)—
52W Range
0.400040% of range5.600
52W High5.600 USD
52W Low0.4000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-52.85%
ROA-28.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.00M $
CapEx (TTM)581.00K $
FCF Margin—
FCF Yield-281.40%
Net Debt9.82M $
Net Debt/EBITDA-0.81
Balance Sheet
Debt/Equity0.38
Current Ratio3.31
Quick Ratio2.76
Book Value/Sh3.841 USD
Cash/Share2.254 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:17
Split DateMar 7, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.3.20M
Float3.00M
Insiders1.98%
Institutions14.77%
Short Interest
Short Ratio0.3d
Short % Float4.91%
Short % Out.4.85%
Shares Short155.24K
Short (prev mo.)149.79K
Technical
SMA 500.7007 (+255.4%)
SMA 2001.368 (+82.0%)
Beta1.83
S&P 52W Chg19.64%
Avg Vol (30d)399.06K
Avg Vol (10d)206.17K
Technical Indicators
RSI (14)36.5
MACD-0.0637
MACD Signal-0.0741
MACD Hist.+0.0104
BB Upper0.5840 USD
BB Middle0.5305 USD
BB Lower0.4770 USD
BB Width20.16%
ATR (14)0.0725 USD
Vol Ratio (20d)0.25x